



King's Research Portal

DOI:

[10.1021/acs.bioconjchem.5b00335](https://doi.org/10.1021/acs.bioconjchem.5b00335)

Document Version

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Ma, M. T., Cullinane, C., Imberti, C., Baguña Torres, J., Terry, S. Y. A., Roselt, P., Hicks, R. J., & Blower, P. J. (2016). New tris(hydroxypyridinone) bifunctional chelators containing isothiocyanate groups provide a versatile platform for rapid one-step labeling and PET imaging with $^{68}\text{Ga}^{3+}$. *Bioconjugate Chemistry*, 27, 309–318. <https://doi.org/10.1021/acs.bioconjchem.5b00335>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

New Tris(hydroxypyridinone) Bifunctional Chelators Containing Isothiocyanate Groups Provide a Versatile Platform for Rapid One-Step Labeling and PET Imaging with $^{68}\text{Ga}^{3+}$

Michelle T. Ma,^{*,†} Carleen Cullinane,^{‡,§} Cinzia Imberti,[†] Julia Baguña Torres,[†] Samantha Y. A. Terry,[†] Peter Roselt,[‡] Rodney J. Hicks,^{‡,§} and Philip J. Blower[†]

[†]King's College London, Division of Imaging Sciences and Biomedical Engineering, Fourth Floor Lambeth Wing, St Thomas' Hospital, London SE1 7EH, United Kingdom


[‡]Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia

[§]Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3010, Australia

S Supporting Information

ABSTRACT: Two new bifunctional tris(hydroxypyridinone) (THP) chelators designed specifically for rapid labeling with ^{68}Ga have been synthesized, each with pendant isothiocyanate groups and three 1,6-dimethyl-3-hydroxypyridin-4-one groups. Both compounds have been conjugated with the primary amine group of a cyclic integrin targeting peptide, RGD. Each conjugate can be radiolabeled and formulated by treatment with generator-produced $^{68}\text{Ga}^{3+}$ in over 95% radiochemical yield under ambient conditions in less than 5 min, with specific activities of 60–80 MBq nmol⁻¹.

Competitive binding assays and in vivo biodistribution in mice bearing U87MG tumors demonstrate that the new $^{68}\text{Ga}^{3+}$ -labeled THP peptide conjugates retain affinity for the $\alpha_v\beta_3$ integrin receptor, clear within 1–2 h from circulation, and undergo receptor-mediated tumor uptake in vivo. We conclude that bifunctional THP chelators can be used for simple, efficient labeling of ^{68}Ga biomolecules under mild conditions suitable for peptides and proteins.



INTRODUCTION

The generator-produced positron-emitting isotope gallium-68 (^{68}Ga) possesses a decay profile ($t_{1/2} = 68$ min, 90% positron yield, 1.9 MeV) that makes it suitable for molecular imaging with positron emission tomography (PET) using peptide-based targeting agents.^{1–3} The advent of an approved pharmaceutical grade $^{68}\text{Ge}/^{68}\text{Ga}$ generator³ (^{68}Ge $t_{1/2} = 270$ days) allows hospitals economical access to a PET isotope without expensive cyclotron facilities. Indeed, current clinical use of ^{68}Ga tracers for neuroendocrine (^{68}Ga -DOTATATE) and prostate (^{68}Ga -HBED-PSMA) tumor-targeting radiopharmaceuticals has had significant impact in the management of patients.^{4–9}

The macrocycle 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), utilized in ^{68}Ga -DOTATATE, has been extensively used in radiolabeled $^{68}\text{Ga}^{3+}$ PET tracers despite the fact that elevated temperatures are required to achieve quantitative radiochemical yield, and some clinical productions of ^{68}Ga -DOTATATE require a postsynthetic purification step^{1,2,10–12} which adds undesirable complexity to the radiopharmaceutical preparation, creating a barrier to widespread implementation of ^{68}Ga PET. To allow for simplification of labeling, alternative bifunctional chelators for $^{68}\text{Ga}^{3+}$ have been designed. These include bifunctional chelators based on 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA and NODAGA),^{13–20} 1,4,7-triazacyclononane macrocycles substituted with phosphinic acid groups at the amine (TRAP and


NOPO),^{21–27} hexaazamacrocyclic,²⁸ a pyridyl-substituted DOTA macrocycle (PCTA),^{10,29} bis(2-hydroxybenzyl)-ethylenediaminediacetic acid (HBED), and related compounds (notably HBED-CC) possessing phenol, amine, and carboxyl donor groups,^{4,30} substituted 6-amino-perhydrodiazepines (AAZTA),³¹ a siderophore-derived macrocyclic chelator with hydroxamate groups (FSC),³² and an acyclic chelator based on a substituted pyridine carboxylate with an N_4O_2 binding mode (DEDPA).^{33–35} Derivatives of NOTA/NODAGA, TRAP/NOPO, HBED, FSC, AAZTA, and DEDPA conjugates have demonstrated desirable radiolabeling properties, with labeling proceeding at room temperature for all these chelators. We have described a tripodal ligand containing three 1,6-dimethyl-3-hydroxypyridin-4-one groups ($\text{H}_3\text{THP-Ac}$) that, upon loss of three protons, coordinates $^{68}\text{Ga}^{3+}$ via 6 O-atoms at pH 6–7 and low ligand concentrations (10 μM) in <5 min (Chart 1).³⁶ This chelator can be radiolabeled quantitatively and faster, at lower chelator concentration and under conditions that are milder³⁶ (ambient temperature without acidic pH) than other chelators such as DOTA and NOTA that are commonly employed for

Special Issue: Molecular Imaging Probe Chemistry

Received: June 14, 2015

Revised: August 13, 2015

Published: August 18, 2015

Chart 1. Structures of H₃THP-Ac and H₃-THP-mal

$^{68}\text{Ga}^{3+}$ and that typically require acidic conditions (pH 2–5) and, in the case of DOTA, high temperatures ($\geq 80^\circ\text{C}$) to achieve quantitative labeling.^{10–13} A maleimide derivative of this chelator (for conjugation to thiol groups) has been prepared (H₃THP-mal, Chart 1),^{36,37} ^{68}Ga -labeled conjugates of which demonstrated high in vivo stability over 90 min with respect to metal complex integrity.


To increase the versatility of this unique chelation system to enable labeling of noncysteine-containing biomolecules, including small proteins and antibodies, new derivatives are required. We report the synthesis of two new tris(hydroxypyridinone) chelators based on 1,6-dimethyl-3-hydroxypyridin-4-one groups that contain pendant isothiocyanates for conjugation to primary amines, and their use for labeling exemplar peptide conjugates with ^{68}Ga for PET imaging.

RESULTS

Synthesis and Radiolabeling of Peptide Conjugates.

To synthesize H₃THP-NCS (Scheme 1), (1)³⁸ was reacted

Scheme 1. Synthesis of Tris(hydroxypyridinone) Bifunctional Chelators Containing Isothiocyanate Groups, H₃THP-NCS (top) and H₃THP-PhNCS (bottom)



with triethylamine and carbon disulfide in ethanol, to give a precipitated dithiocarbamate intermediate upon addition of water.³⁹ The precipitated intermediate was resuspended in a solution of carbon disulfide/ethanol and addition of di-*tert*-butyl dicarbonate and a catalytic amount of 4-dimethylaminopyridine resulted in formation of (2). Subsequent removal of the benzyl groups with boron trichloride in dichloromethane, followed by addition of trifluoroethanol resulted in H₃THP-NCS. To synthesize H₃THP-PhNCS (Scheme 1), an excess of *p*-phenylene diisothiocyanate and diisopropylethylamine in dimethylformamide were added to a solution of (1), followed

by isolation of (3) using reverse-phase semipreparative high-performance liquid chromatography (HPLC). The benzyl groups of (3) were removed using boron trichloride in dichloromethane, followed by addition of methanol, resulting in the bifunctional chelator H₃THP-PhNCS.

The $\alpha_v\beta_3$ integrin-targeting pentapeptide, cyclic(RGDfK) (RGD), was chosen as an appropriately well-characterized peptide targeting vector⁴⁰ for conjugation to the new tris(hydroxypyridinone) bifunctional chelators. Both H₃THP-NCS and H₃THP-PhNCS were reacted with the primary amine of the lysine side chain of RGD under microwave conditions similar to those often employed for peptide synthesis (dimethyl sulfoxide containing diisopropylethylamine, 120°C , 300 W, 30 min). Use of dimethylformamide as a solvent in place of dimethyl sulfoxide resulted in precipitation of the bifunctional chelator upon addition of base, and no reaction took place, necessitating the use of dimethyl sulfoxide as a solvent. The reaction products were purified using semipreparative HPLC. Both conjugates H₃THP-NCS-RGD and H₃THP-PhNCS-RGD (Figure 1a,c) were isolated in 98% purity.

Both peptide derivatives could be radiolabeled with generator-produced eluate that was added either directly from the generator, or eluate that was preconditioned to concentrate activity and remove any contaminating ^{68}Ge . In the case of the former, addition of generator-produced $^{68}\text{Ga}^{3+}$ (90–110 MBq, Eckert and Ziegler generator) in aqueous HCl (0.1 M, 1 mL) to the tris(hydroxypyridinone) conjugates (10–12 nmol) at ambient temperature, followed by addition of aqueous ammonium acetate (1 M, 300 μL) to obtain solutions of pH ~ 6.5 , provided ^{68}Ga -labeled conjugate. Within 2–5 min of addition of $^{68}\text{Ga}^{3+}$ to the conjugates, the solutions were subjected to analytical reverse-phase HPLC analysis. Each reaction mixture gave a single peak in the HPLC radiochromatogram (Figure 1b,d, red traces), and in these experiments, in which a low activity generator was utilized, the radiochemical yield measured $>99\%$, with specific activities of 8–9 MBq nmol⁻¹.

For radiolabeling conjugates for in vivo studies, a generator eluting higher activities was employed, and eluate was subjected to pretreatment prior to radiolabeling to remove ^{68}Ge .⁴¹ Generator-produced $^{68}\text{Ga}^{3+}$ (800–1000 MBq, iThemba Laboratories generator) was concentrated on an AG 50W $\times 4$ cation exchange cartridge, and eluted with 200 μL 0.9 M HCl in ethanol/water (90%/10%).⁴¹ This volume was diluted in deionized water (800 μL) and directly added to H₃THP-NCS-RGD and H₃THP-PhNCS-RGD (~ 12 nmol) at ambient temperature, followed immediately by addition of aqueous ammonium acetate (2 M, 400 μL) and saline to obtain solutions of pH ~ 6.5 , resulting in solutions of [^{68}Ga (THP-NCS-RGD)] and [^{68}Ga (THP-PhNCS-RGD)]. Within 2–5 min of addition of $^{68}\text{Ga}^{3+}$ to the conjugates, the solutions were subjected to analytical reverse-phase HPLC and instant thin layer chromatography (ITLC) analysis. Each reaction mixture gave a single major peak in the HPLC radiochromatogram (Figure S1), and under these conditions, the radiochemical yield for all of these reactions was $>95\%$ (determined by ITLC), with specific activities of 60–80 MBq nmol⁻¹.

To verify the identity of the radiolabeled products, the ^{68}Ga -labeled conjugates and their nonradioactive (^{nat}Ga) analogs were analyzed using analytical reverse-phase HPLC with UV and sodium iodide scintillation detection. H₃THP-NCS-RGD eluted earlier than [$^{nat/68}\text{Ga}$ (THP-NCS-RGD)] (Figure 1b, black trace, retention time of 7.15 min). Co-elution of




Figure 1. (a) $\text{H}_3\text{THP-NCS-RGD}$; (b) HPLC traces (λ_{220}) of $\text{H}_3\text{THP-NCS-RGD}$ (black) and $[\text{natGa}(\text{THP-NCS-RGD})]$ (blue), and radio-HPLC trace of $[\text{natGa}(\text{THP-NCS-RGD})]$ (red). Inset: Mass spectral signal of $[\text{natGa}(\text{THP-NCS-RGD}) + 2\text{H}]^{2+}$; (c) $\text{H}_3\text{THP-PhNCS-RGD}$; (d) HPLC traces (λ_{220}) of $\text{H}_3\text{THP-PhNCS-RGD}$ (black) and $[\text{natGa}(\text{THP-PhNCS-RGD})]$ (blue), and radio-HPLC trace of $[\text{natGa}(\text{THP-PhNCS-RGD})]$ (red). Inset: Mass spectral signal of $[\text{natGa}(\text{THP-PhNCS-RGD}) + 2\text{H}]^{2+}$.

$[\text{natGa}(\text{THP-NCS-RGD})]$ (Figure 1b, blue trace, retention time of 7.57 min) with $[\text{natGa}(\text{THP-NCS-RGD})]$ (red trace, retention time of 7.83 min) confirmed the identity of the radiolabeled compound, with the difference in retention time a result of the configuration of the different detectors in series. Only a single signal was observed in the liquid chromatography/mass spectrometry (LCMS) total ion count chromatogram, corresponding to $[\text{natGa}(\text{THP-NCS-RGD})]$ (Figure 1b, inset). The dipositive ion ($[\text{natGa}(\text{THP-NCS-RGD}) + 2\text{H}]^{2+}$: $\{\text{C}_{65}\text{H}_{90}\text{N}_{17}\text{O}_{17}\text{SGa}\}^{2+}$, observed monoisotopic peak = 740.78, calculated = 740.78) was the strongest in the spectrum, but the corresponding tripositive and monopositive species were also observed. Similarly, a solution containing $[\text{natGa}(\text{THP-PhNCS-RGD})]$ resulted in a signal in the UV chromatogram with a retention time of 8.15 min, matching that of $[\text{natGa}(\text{THP-PhNCS-RGD})]$ (8.35 min, radiochromatogram), and distinct from $\text{H}_3\text{THP-PhNCS-RGD}$ (7.80 min) (Figure 1d). A single signal was observed in the LCMS total ion count chromatogram, corresponding to $[\text{natGa}(\text{THP-PhNCS-RGD})]$, and the major peak in the associated mass spectrum was the dipositive ion ($[\text{natGa}(\text{THP-PhNCS-RGD}) + 2\text{H}]^{2+}$: $\{\text{C}_{72}\text{H}_{96}\text{N}_{19}\text{O}_{17}\text{S}_2\text{Ga}\}^{2+}$, observed monoisotopic peak = 815.80, calculated 815.80). No Ga^{3+} complexes with metal/ligand stoichiometry other than 1:1 were detected in any fraction eluting from the HPLC column in either case.

Serum stability studies were undertaken to determine whether $[\text{natGa}(\text{THP-NCS-RGD})]$ or $[\text{natGa}(\text{THP-PhNCS-RGD})]$ release Ga^{3+} to endogenous serum proteins. Addition of generator-produced Ga^{3+} to a solution of human serum resulted in Ga^{3+} -bound protein and small molecule adducts that possessed distinct retention times of 5.9, 9.1, and 13.1 min when applied to the size exclusion HPLC column utilized in this study (Figure S2a). Under the same conditions, the radiolabeled peptide conjugates $[\text{natGa}(\text{THP-NCS-RGD})]$ and $[\text{natGa}(\text{THP-PhNCS-RGD})]$ possessed retention times of 18.1 and 20.2 min, respectively (Figure S2b,d). Both $[\text{natGa}(\text{THP-NCS-RGD})]$ and $[\text{natGa}(\text{THP-PhNCS-RGD})]$ were incubated in fresh human serum at 37 °C, and at 1 and 4 h, aliquots of these serum solutions were applied directly to the size exclusion HPLC column. Size exclusion chromatograms acquired at 1


and 4 h time points exhibited single signals with the same retention times as the control samples of $[\text{natGa}(\text{THP-NCS-RGD})]$ and $[\text{natGa}(\text{THP-PhNCS-RGD})]$, indicating that no transchelation of Ga^{3+} from peptide conjugate to serum constituents occurred in either case (Figure S2c,e).

In vivo metabolic stability studies were also performed in Balb/c mice to assess whether $[\text{natGa}(\text{THP-NCS-RGD})]$ or $[\text{natGa}(\text{THP-PhNCS-RGD})]$ are modified, metabolized, or degraded while in circulation. Blood samples were obtained 20 and 90 min postinjection (PI), the serum fraction was separated from erythrocytes, serum proteins precipitated, and the supernatant applied to an analytical reverse-phase HPLC column. The acquired chromatograms revealed single signals for each trace, and each signal possessed a retention time that matched that of the administered radiotracer (Figures S3a-c and S4a-c). Urine was also collected and analyzed by reverse-phase HPLC (Figures S3d and S4d). While signals corresponding to the retention time of the administered radiotracers were observed in the chromatograms for both conjugates, several other broad signals were observed. These data indicated that both $[\text{natGa}(\text{THP-NCS-RGD})]$ and $[\text{natGa}(\text{THP-PhNCS-RGD})]$ were metabolically stable in circulation in vivo over a period of 90 min; however, renal clearance pathways for both radiotracers involved significant metabolism of both $[\text{natGa}(\text{THP-NCS-RGD})]$ and $[\text{natGa}(\text{THP-PhNCS-RGD})]$.

The half-maximal inhibitory concentration (IC_{50}) values of $[\text{Ga}(\text{THP-NCS-RGD})]$, $[\text{Ga}(\text{THP-PhNCS-RGD})]$, and RGD were determined using a solid-phase competitive binding assay with ^{125}I -echistatin. Binding of ^{125}I -echistatin to $\alpha_v\beta_3$ integrin was inhibited by $[\text{Ga}(\text{THP-NCS-RGD})]$, $[\text{Ga}(\text{THP-PhNCS-RGD})]$, and RGD in a concentration-dependent manner demonstrating high binding affinity and specificity of $[\text{Ga}(\text{THP-NCS-RGD})]$, $[\text{Ga}(\text{THP-PhNCS-RGD})]$, and RGD for $\alpha_v\beta_3$ integrin (Table 1, Figure 2). The IC_{50} value of $[\text{Ga}(\text{THP-NCS-RGD})]$ (8.3 ± 1.5 nM) was comparable to that of RGD (8.7 ± 1.6 nM), indicating similar affinity for the $\alpha_v\beta_3$ integrin receptor. The IC_{50} value of $[\text{Ga}(\text{THP-PhNCS-RGD})]$ (4.8 ± 0.6 nM) was lower than that of $[\text{Ga}(\text{THP-NCS-RGD})]$ and RGD, suggesting a higher relative affinity for the $\alpha_v\beta_3$ integrin receptor. Importantly, IC_{50} values indicated that the tris-

Table 1. IC₅₀ Values for [Ga(THP-NCS-RGD)], [Ga(THP-PhNCS-RGD)], and RGD, Determined Using a Solid-Phase Competitive Binding Assay with ¹²⁵I-Echistatin

compound	IC ₅₀ (nM) (±standard error)	95% confidence interval (nM)
[Ga(THP-NCS-RGD)]	8.3 ± 1.5	5.2–11.3
[Ga(THP-PhNCS-RGD)]	4.8 ± 0.6	3.6–5.9
RGD	8.7 ± 1.6	5.5–11.9


Figure 2. Mean concentration response curve for ¹²⁵I-echistatin titrated with [Ga(THP-NCS-RGD)] (black), [Ga(THP-PhNCS-RGD)] (red), and RGD (blue) ($n = 6$ for each concentration; error bars correspond to standard error of the mean).

(hydroxypyridinone) conjugates retain the affinity of the parent peptide for $\alpha_v\beta_3$ integrin receptors.


Biodistribution of ⁶⁸Ga-Labeled Peptide Conjugates.

The biodistribution of [⁶⁸Ga(THP-NCS-RGD)] and [⁶⁸Ga(THP-PhNCS-RGD)] was assessed in Balb/c nu/nu mice bearing $\alpha_v\beta_3$ integrin-positive glioblastoma U87MG tumors ($n = 3$). Each animal was administered 16–21 MBq of tracer

(containing $\sim 1 \mu\text{g}$ of conjugate) and PET scanned at either 1 or 2 h PI for 10 min, followed by euthanasia and organ harvesting for ex vivo radioactivity counting. To assess specificity of the radiotracer, separate groups of animals were coadministered the tracer and RGD (0.4 mg per animal), followed by scanning, euthanasia, and ex vivo organ counting 1 h PI.

In PET scans of mice administered [⁶⁸Ga(THP-NCS-RGD)] 1 h PI (Figure 3a), the tumor was visible, with a tumor to background (mediastinum) concentration ratio of 2.76 ± 0.18 . The kidneys and liver of all animals were also discernible with a tumor to kidney concentration ratio of 1.03 ± 0.05 , and a tumor to liver concentration ratio of 1.59 ± 0.16 . There was no evidence of bone uptake being above that of surrounding muscle. Excretion was largely renal and the bladder was associated with the highest levels of activity in all PET images. Images of animals coadministered RGD demonstrated that RGD effectively blocks $\alpha_v\beta_3$ integrin receptor binding by [⁶⁸Ga(THP-NCS-RGD)].

The ex vivo biodistribution data of [⁶⁸Ga(THP-NCS-RGD)] (Figure 3b) were consistent with PET imaging data. In animals administered solely [⁶⁸Ga(THP-NCS-RGD)], there was significantly higher radioactivity concentration in the tumor than in animals co-administered [⁶⁸Ga(THP-NCS-RGD)] and RGD, indicative of receptor-mediated tumor uptake ($2.35 \pm 0.06\% \text{ID g}^{-1}$, vs $0.62 \pm 0.10\% \text{ID g}^{-1}$, respectively, mean difference = $1.73\% \text{ID g}^{-1}$, 95% CI = $1.45 - 1.99\% \text{ID g}^{-1}$, $p = 6.00 \times 10^{-5}$). Coadministration of RGD also significantly reduced uptake of the tracer at 1 h PI in the heart, liver, spleen, muscle, and lungs (Table S1). At both 1 and 2 h PI, the tumor, kidneys, and liver contained the highest concentration of radioactivity (Figure 3b). At 2 h PI, blood activity had cleared significantly compared to 1 h PI (0.16 ± 0.04 vs $0.84 \pm 0.09\% \text{ID g}^{-1}$, respectively), and in all organs and tissues, decay-corrected activity was slightly decreased compared to 1 h PI.


Figure 3. PET imaging and ex vivo biodistribution of (a) [⁶⁸Ga(THP-NCS-RGD)] and (b) [⁶⁸Ga(THP-PhNCS-RGD)]. Representative PET maximum intensity projection of Balb/c nu/nu mice bearing a U87MG tumor on right flank at (i) 1 h PI of tracer, (ii) 1 h after coinjection of tracer and RGD, and (iii) 2 h PI of tracer, (iv) ex vivo biodistribution in mice at 1 and 2 h PI of tracer, and 1 h PI of tracer coadministered with RGD (blocked); $n = 3$. Error bars correspond to standard error of the mean.

Similarly, PET scans of animals administered [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] demonstrated that [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] accumulated in the tumor, with a tumor to background concentration ratio of 2.34 ± 0.06 , and a tumor to liver concentration ratio of 0.91 ± 0.03 at 1 h PI. There was no evidence of bone uptake being above that of surrounding muscle. Ex vivo biodistribution data demonstrated that there was significantly more activity associated with the tumor for animals administered solely [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] 1 h PI ($2.86 \pm 0.43\% \text{ID g}^{-1}$) than for animals coadministered [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] and RGD ($0.99 \pm 0.12\% \text{ID g}^{-1}$, mean difference = $1.87\% \text{ID g}^{-1}$, 95% CI = $0.86\text{--}2.89\% \text{ID g}^{-1}$, $p = 6.89 \times 10^{-3}$), consistent with $\alpha_v\beta_3$ integrin receptor mediated tumor uptake. Significantly reduced uptake was also observed for the spleen, liver, and muscle in animals coadministered RGD (Table S2). In contrast to [$^{68}\text{Ga}(\text{THP-NCS-RGD})$], uptake of [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] in the tumor, spleen, and liver was slightly higher 2 h PI compared to 1 h PI, while uptake in other organs decreased (Figure 3b-iv). Blood activity at 2 h PI ($0.25 \pm 0.02\% \text{ID g}^{-1}$) was lower than that observed at 1 h PI ($0.57 \pm 0.03\% \text{ID g}^{-1}$). Blood activity at 1 h PI in the group coadministered RGD was significantly higher ($1.29 \pm 0.10\% \text{ID g}^{-1}$) than in the group administered only [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] ($0.57 \pm 0.03\% \text{ID g}^{-1}$) (Table S2).

Tumor uptake of [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] was higher than that of [$^{68}\text{Ga}(\text{THP-NCS-RGD})$] at 1 h PI and 2 h PI (1 h: 2.86 ± 0.43 vs $2.35 \pm 0.06\% \text{ID g}^{-1}$, mean difference = $0.52\% \text{ID g}^{-1}$, 95% CI = $-0.48\text{--}1.51\% \text{ID g}^{-1}$, $p = 0.22$; 2 h: 3.32 ± 0.20 vs $1.90 \pm 0.21\% \text{ID g}^{-1}$, mean difference = $1.41\% \text{ID g}^{-1}$, 95% CI = $0.75\text{--}2.08\% \text{ID g}^{-1}$, $p = 4.15 \times 10^{-3}$, respectively). This is consistent with the lower IC_{50} value determined for [$\text{Ga}(\text{THP-PhNCS-RGD})$] relative to [$\text{Ga}(\text{THP-NCS-RGD})$]. The observed higher affinity of [$\text{Ga}(\text{THP-PhNCS-RGD})$] (both in the solid-phase binding assay and in vivo) is possibly a result of the greater distance between the tris(hydroxypyridinone) complex and the RGD motif in [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] compared to [$^{68}\text{Ga}(\text{THP-NCS-RGD})$].

Similarly, accumulation of radioactivity in the liver and spleen is higher in animals administered [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] compared with animals administered [$^{68}\text{Ga}(\text{THP-NCS-RGD})$] at both 1 and 2 h PI. This difference in accumulation of the two tracers in the liver and spleen could be a result of two factors: (i) the increased $\alpha_v\beta_3$ integrin affinity of [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] relative to [$^{68}\text{Ga}(\text{THP-NCS-RGD})$], and/or (ii) increased nonspecific uptake of [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] in the liver and spleen compared to [$^{68}\text{Ga}(\text{THP-NCS-RGD})$]. There is some evidence in support of the latter—in the blockade experiments, uptake of [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] is higher than uptake of [$^{68}\text{Ga}(\text{THP-NCS-RGD})$] in both the liver (2.68 ± 0.12 vs $1.30 \pm 0.16\% \text{ID g}^{-1}$) and spleen (0.82 ± 0.03 vs $0.42 \pm 0.09\% \text{ID g}^{-1}$).

DISCUSSION

Simplicity and efficiency of labeling is a key to wider adoption of ^{68}Ga PET in hospitals. The new bifunctional chelators, $\text{H}_3\text{THP-NCS}$ and $\text{H}_3\text{THP-PhNCS}$, enable a facile, single-step route for preparation of peptide conjugates containing a tris(hydroxypyridinone) chelator. We chose to attach these new bifunctional chelators to the $\alpha_v\beta_3$ integrin-targeting peptide RGD to evaluate the radiolabeling and biodistribution profile of a simple tris(hydroxypyridinone) peptide conjugate and to establish whether such conjugates retain their receptor targeting affinity in vivo. Conjugation via the pendant

isothiocyanate proceeds under microwave conditions frequently employed in peptide synthesis.⁴²

The ^{68}Ga -radiolabeling of $\text{H}_3\text{THP-NCS-RGD}$ and $\text{H}_3\text{THP-PhNCS-RGD}$ could be accomplished at ambient temperatures simply by addition of acidic solutions of generator-produced $^{68}\text{Ga}^{3+}$ to solutions of the conjugates, followed by addition of ammonium acetate. High radiochemical yields (>95%) and specific activities ($60\text{--}80 \text{ MBq nmol}^{-1}$) were achieved, circumventing the requirement for postsynthetic purification. These uniquely efficient, simple, and mild radiolabeling properties would afford exceptionally rapid radiochemical synthesis of a ^{68}Ga radiopharmaceutical and are conducive to translation to a one-step, kit-based preparation of a peptidic ^{68}Ga -labeled radiotracer based on a tris(hydroxypyridinone) conjugate.

Serum and metabolic stability data indicate that both [$^{68}\text{Ga}(\text{THP-NCS-RGD})$] and [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] are stable to $^{68}\text{Ga}^{3+}$ transchelation to serum proteins, as well as degradation or modification of the conjugates while in circulation, respectively. Furthermore, PET scans and ex vivo biodistribution data in Balb/c nu/nu mice bearing glioblastoma U87MG $\alpha_v\beta_3$ integrin-positive tumors indicate that both [$^{68}\text{Ga}(\text{THP-NCS-RGD})$] and [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] retain affinity for $\alpha_v\beta_3$ integrin receptors in vivo. Ex vivo biodistribution data are consistent with the expression profile of $\alpha_v\beta_3$ integrin, which is expressed in tumors including late stage glioblastomas, angiogenesis,⁴³ and at low levels in normal vascular tissue.⁴⁰

Animals coadministered RGD demonstrate that RGD effectively blocks $\alpha_v\beta_3$ integrin receptor binding by both [$^{68}\text{Ga}(\text{THP-NCS-RGD})$] and [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] in tumors, and as such, tumor uptake of the new radiotracers is receptor-mediated. Biodistribution data also indicate significant receptor-mediated uptake in the liver and spleen for both radiotracers, and in the heart, muscle, and lungs for [$^{68}\text{Ga}(\text{THP-NCS-RGD})$]. Similar decreased uptake in blockade experiments for the liver, spleen, heart, lungs, muscles, adrenals, and intestines has been previously observed with other RGD conjugates labeled with PET isotopes ^{68}Ga , ^{64}Cu , ^{18}F , and ^{44}Sc .^{19,20,26,27,44,45} Tumor uptake of [$^{68}\text{Ga}(\text{THP-NCS-RGD})$] (1 h: $2.35 \pm 0.06\% \text{ID g}^{-1}$, 2 h: $1.90 \pm 0.21\% \text{ID g}^{-1}$) and [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] (1 h: 2.86 ± 0.43 , 2 h: 3.32 ± 0.20) is comparable to that of other conjugates of RGD reported in U87MG tumor bearing mice, although generally tumor to nontarget organ ratios, notably the liver, are lower for the tris(hydroxypyridinone) conjugates. ^{68}Ga -labeled conjugates of RGD demonstrate receptor-mediated tumor uptake at 1 h PI of $5.19 \pm 1.45\% \text{ID g}^{-1}$ for $^{68}\text{Ga-NODAGA-RGD}$ and $3.47 \pm 0.78\% \text{ID g}^{-1}$ for $^{68}\text{Ga-DOTA-RGD}$. Similar accumulation is observed for ^{64}Cu -labeled analogs.²⁰ The ^{18}F -galacto-RGD PET tracer has an uptake of $1.16\% \text{ID g}^{-1}$ 1 h PI, but significantly lower nontarget organ uptake.⁴⁶ The dimeric conjugate containing two $\alpha_v\beta_3$ integrin targeting cyclic-(RGDyK) groups, $^{68}\text{Ga-NODAGA-E}(\text{RGDyK})_2$, demonstrates receptor mediated accumulation, with U87MG tumor uptake measuring $2.23 \pm 0.08\% \text{ID g}^{-1}$ 1 h PI and liver uptake of $2.97 \pm 0.39\% \text{ID g}^{-1}$,¹⁹ values comparable to the monomeric tracers described here.

CONCLUDING REMARKS

The new bifunctional chelators, $\text{H}_3\text{THP-NCS}$ and $\text{H}_3\text{THP-PhNCS}$, enable a facile route for preparation of conjugates

containing a tris(hydroxypyridinone) chelator, and the conjugates retain the uniquely efficient radiolabeling properties reported for the maleimide derivative,³⁶ affording exceptionally rapid radiochemical synthesis of a ⁶⁸Ga radiopharmaceutical under mild conditions without the need for subsequent purification. Ga³⁺-complexed conjugates of RGD retain affinity for $\alpha_v\beta_3$ integrin receptors, and provide PET images that allow clear delineation of $\alpha_v\beta_3$ integrin-positive tumors. The efficiency of labeling tris(hydroxypyridinone) chelators at very low concentrations and under mild conditions brings the possibility of kit-based production of ⁶⁸Ga PET tracers, including sensitive proteins, without complex automated synthesis typical of multistep PET radiochemistry. This would greatly increase ⁶⁸Ga PET access to hospitals that lack expertise or facilities to implement such automated synthetic technologies but are adept in preparation of kit-based radiopharmaceuticals—notably radiopharmacy laboratories routinely producing ^{99m}Tc radiopharmaceuticals. Thus, such kit-based technologies will expand the use of the ⁶⁸Ga generator for the benefit of more hospitals and patients.

■ EXPERIMENTAL PROCEDURES

Materials and Instrumentation. Chemicals and reagents were obtained from Sigma-Aldrich (Dorset, UK) unless otherwise specified. High-performance liquid chromatography (HPLC) analysis was carried out using an Agilent 1200 LC system with in-line UV and gamma detection (Flow-Count, LabLogic). NMR spectra were acquired on a Bruker Avance 400 spectrometer (Bruker UK Limited, Coventry, UK) equipped with a 5 mm QNP probe at 400.13 MHz for ¹H NMR spectra (using a zg30 pulse program) and 100.6 MHz for ¹³C NMR spectra (using a zgpg30 pulse program). Spectra were referenced to residual solvent signals. Mass spectra were recorded in the positive ion mode on an Agilent 6510 Q-TOF LC/MS mass spectrometer coupled to an Agilent 1200 LC system (Agilent, Palo Alto, CA). Data were acquired and reference mass-corrected via a dual-spray electrospray ionization source, using the factory-defined calibration procedure. Analytical reverse-phase LCMS and radio-LCMS traces were acquired using an Eclipse XDB-C18 column (4.6 × 150 mm, 5 μ m) with a 1 mL min⁻¹ flow rate. Instant thin layer chromatography strips (ITLC-SG) were obtained from Varian Medical Systems UK, Ltd. (Crawley, UK), and ITLC strips were visualized using a Raytest Rita-Star TLC scanner. Semipreparative reverse-phase HPLC was conducted using an Agilent Eclipse XDB-C18 column (9.4 × 250 mm, 5 μ m) coupled to an Agilent 1200 LC system, with a 3 mL min⁻¹ flow rate and UV spectroscopic detection at 220 nm. Mobile phase A contained water with 0.2% TFA and mobile phase B contained acetonitrile with 0.2% TFA. All methods started with 100% A at 0 min. For method 1, the concentration of B increased at a rate of 1% min⁻¹, and for method 2, the concentration of B increased at a rate of 0.5% min⁻¹. Analytical reverse-phase HPLC and radio-HPLC traces were acquired using two different instruments: (1) an Agilent 1200 LC system and an Agilent Zorbax Eclipse XDB-C18 column (4.6 × 150 mm, 5 μ m) with a 1 mL min⁻¹ flow rate and UV spectroscopic detection at either 214 or 220 nm. The radio-HPLC was coupled to a LabLogic Flow-Count detector with a sodium iodide probe (B-FC-3200). Aliquots (10–200 μ L) of each radiolabeled sample were injected onto the column, using a flow rate of 1 mL min⁻¹. Mobile phase A contained water with

0.1% TFA and mobile phase B contained acetonitrile with 0.1% TFA. For method 3, the concentration of B increased at a rate of 5% min⁻¹, with 100% A at 0 min, and 100% B at 20 min. (2) An Agilent Zorbax Eclipse XDB-C18 column (4.6 × 150 mm, 5 μ m) with a 1 mL min⁻¹ flow rate and UV spectroscopic detection at either 214 or 220 nm coupled to a Shimadzu HPLC consisting of a SCL-10AVP system controller, a SIL-10ADVP autoinjector, a LC-10 ATVP solvent delivery unit, a FCV-10AL control valve, a DGU-14A degasser, and a SPD-10AVP UV detector. This was coupled to a radiation detector consisting of an Ortec model 276 Photomultiplier Base with Preamplifier, Amplifier, BIAS supply and SCA and a Bicon 1 M 11.2 Photomultiplier Tube. For method 4, the concentration of B increased at a rate of 6.67% min⁻¹, with 100% A at 0 min, and 80% B at 12 min. For initial radiolabeling and characterization studies that utilized <400 MBq, an Eckert and Ziegler ⁶⁸Ge/⁶⁸Ga generator (Berlin, Germany) was used. For biodistribution studies, and experiments that utilized >600 MBq ⁶⁸Ga, an iThemba Laboratories 1.8 GBq ⁶⁸Ge/⁶⁸Ga generator (IDB Holland BV, Netherlands) was used. Analytical size exclusion radio-HPLC traces were acquired using an Agilent 1200 Series HPLC system and a Phenomenex Biosep 2000 (300 × 7.8 mm) size exclusion column with a phosphate buffered saline mobile phase with a flow rate of 1 mL min⁻¹.

Synthesis. Compound 2. Compound 1 (synthesized according to previously reported procedures³⁸) (100 mg, 96 μ mol) was dissolved in ethanol (5 mL), and carbon disulfide (60 μ L, 12 equiv) and triethylamine (13.4 μ L, 1 equiv) were added.³⁹ Addition of water (5 mL) resulted in formation of a white precipitate, corresponding to the dithiocarbamate intermediate. Excess carbon disulfide was removed under reduced pressure, and the remaining solution frozen and lyophilized. The dry residue was resuspended in ethanol (5 mL) containing carbon disulfide (60 μ L) and triethylamine (13.4 μ L). Di-*tert*-butyl dicarbonate (4 equiv, 21 mg) and 4-dimethylaminopyridine (2–3% molar equiv) were added,³⁹ and the reaction stirred at room temperature for 6 h. The reaction mixture was evaporated to dryness, the residue dissolved in water/acetonitrile (60%/40%) and applied to a semipreparative reverse-phase Agilent Eclipse XDB-C18 column (9.4 × 250 mm, 5 μ m) with a 3 mL min⁻¹ flow rate and UV spectroscopic detection at 220 nm. Using HPLC method 1, 1 eluted with 40% B (40 min). Fractions containing the desired product were lyophilized. Yield = 50 mg, 48%. ¹H NMR ((CD₃)₂SO, 400 MHz): δ 1.80 (m, 6H), 2.05 (m, 6H), 2.45 (t, *J* = 6.37, 2H), 2.55 (s, 9H), 3.75 (broad, 2H), 3.75 (s, 9H), 4.53 (d, *J* = 5.06, 6H), 5.13 (s, 6H), 7.13 (s, 3H), 7.35–7.48 (m, 15H + NH), 8.30 (t, *J* = 5.06, 3NH). ¹³C NMR ((CD₃)₂SO, 100 MHz): δ 20.4, 28.9, 29.6, 34.5, 35.4, 38.5, 41.1, 56.6, 74.0, 114.6, 127.5, 128.1, 128.2, 128.3, 136.1, 142.9, 146.3, 151.5, 165.0, 167.9, 171.2. ESI-MS: *m/z* for C₅₉H₆₈N₈O₁₀S + H⁺ calc 1081.48, found 1081.48.

H₃THP-NCS. A solution of chilled boron trichloride in dichloromethane (10 mL, 1 M) was added to a sealed vial containing compound 2 (46 mg, 43 μ mol), and the reaction was stirred at ambient temperature for 1 h. The reaction vial was then cooled in an ice bath, and trifluoroethanol (3 mL) was added dropwise to the flask. The reaction solution was evaporated to dryness, and the residue dissolved in water/acetonitrile (80%/20%) and filtered. The filtrate was diluted to 10 mL using a solution of 0.2% TFA in water, and applied to a semipreparative HPLC column. Using HPLC method 2, H₃THP-NCS eluted with 17–18% B (37 min). Fractions

containing the desired product were lyophilized. Yield of trifluoroacetate salt = 25 mg, 47% yield. ^1H NMR ($(\text{CD}_3)_3\text{SO}$, 400 MHz): δ 1.82 (m, 6H), 2.08 (m, 6H), 2.45 (t, J = 6.41 2H), 2.52 (s, 9H), 3.77 (t, J = 6.41, 2H), 3.80 (s, 9H), 4.54 (d, J = 5.21, 6H), 6.97 (s, 3H), 7.43 (s, 1NH), 8.47 (t, J = 5.21, 3NH). ^{13}C NMR ($(\text{CD}_3)_3\text{SO}$, 100 MHz): δ 20.3, 25.5, 28.8, 34.4, 35.4, 38.3, 41.1, 57.0, 112.4, 127.8, 138.6, 143.2, 148.3, 160.9, 168.2, 173.1. ESI-MS: m/z for $\text{C}_{38}\text{H}_{50}\text{N}_8\text{O}_{10}\text{S} + \text{H}^+$ calc 811.34, found 811.36.

Compound 3. An excess of *p*-phenylene diisothiocyanate (40 mg) and diisopropylethylamine (40 μL) in DMF (0.5–1 mL) were added to a solution of **1** (40 mg, 39 μmol) in DMF (0.5–1 mL). The reaction solution was agitated, and after 5–10 min, applied to a semipreparative HPLC column. Using HPLC method 1, **3** eluted with 42% B (42 min). Fractions containing the desired product were lyophilized. Yield = 39 mg, 81% yield. ^1H NMR (CD_3OD , 400 MHz): δ 1.94 (m, 6H), 2.15 (m, 6H), 2.46 (t, J = 6.14, 2H), 2.60 (s, 9H), 3.79 (broad, 2H), 3.84 (s, 9H), 4.60 (s, 6H), 5.20 (s, 6H), 7.17 (d, J = 8.79, 2H), 7.33–7.46 (15H), 7.41 (d, J = 8.79, 2H). ^{13}C NMR (CD_3OD , 100 MHz): δ 21.4, 30.7, 31.0, 36.5, 36.9, 39.9, 42.1, 59.1, 76.3, 116.2, 125.7, 127.1, 128.6, 129.7, 129.9, 130.0, 136.6, 137.5, 145.0, 148.4, 154.1, 166.6, 173.6, 175.4, 182.0. ESI-MS: m/z for $\text{C}_{66}\text{H}_{74}\text{N}_{10}\text{O}_{10}\text{S}_2 + 2\text{H}^+$ calc 616.26, found 616.26.

$\text{H}_3\text{TTHP-PhNCS}$. A solution of chilled boron trichloride in dichloromethane (5 mL, 1 M) was added to a sealed vial containing compound **3** (20 mg, 16 μmol), and the reaction was stirred at ambient temperature for 1 h. The reaction vial was then cooled in an ice bath, and methanol (5–10 mL) was added dropwise to the flask. The reaction solution was evaporated to near dryness under reduced pressure, and acetone (50 mL) was added to the residue, resulting in a flocculant white precipitate. This suspension was transferred to a 50 mL centrifugal tube, and the mixture centrifuged at 3000 rpm for 10 min. After this, the solution was decanted and discarded, acetone added (50 mL), the suspension agitated, and centrifuged again for 10 min. This process of washing with acetone was repeated again. Finally, the product was dissolved in water/acetonitrile (50/50), filtered, frozen and lyophilized. Yield = 10 mg, 58% yield. ^1H NMR (CD_3OD , 700 MHz): δ 1.98 (m, 6H), 2.22 (m, 6H), 2.49 (t, J = 6.13 2H), 2.59 (s, 9H), 3.82 (broad, 2H), 3.93 (s, 9H), 4.69 (s, 6H), 7.00 (s, 3H), 7.23 (d, J = 8.44, 2H), 7.43 (d, J = 8.44, 2H). ^{13}C NMR (CD_3OD , 175 MHz): δ 21.1, 30.6, 31.0, 36.3, 36.9, 39.5, 42.2, 59.1, 114.1, 125.8, 127.2, 128.8, 136.8, 139.4, 140.0, 145.2, 150.4, 162.2, 173.6, 176.3, 182.1. ESI-MS: m/z for $\text{C}_{45}\text{H}_{56}\text{N}_{10}\text{O}_{10}\text{S}_2 + \text{H}^+$ calc 961.37, found 961.37.

Synthesis of RGD Conjugates. The cyclic peptide cyclic-(RGDfK) (RGD) was dissolved in dimethyl sulfoxide (100–300 μL) and added to a solution of either $\text{H}_3\text{TTHP-NCS}$ or $\text{H}_3\text{TTHP-PhNCS}$ in dimethyl sulfoxide (100–300 μL), and diisopropylethylamine (5–10 μL) was added. The reaction solutions were heated in a microwave (120 $^\circ\text{C}$, 300 W, 30 min) and then applied to a reverse-phase HPLC column. Fractions containing the desired conjugate in sufficient purity were combined and lyophilized. Using HPLC method 2, $\text{H}_3\text{TTHP-NCS-RGD}$ eluted with 21% solvent B (42 min) and $\text{H}_3\text{TTHP-PhNCS-RGD}$ eluted with 23% solvent B (47 min). Isolated yields = 30–40%. $\text{H}_3\text{TTHP-NCS-RGD}$: ESI-MS: m/z for $\text{C}_{65}\text{H}_{91}\text{N}_{17}\text{O}_{17}\text{S} + 3\text{H}^+$ calc 472.22, found 472.22; HPLC: 220 nm, RT = 7.15 min, >98% purity (HPLC method 3). $\text{H}_3\text{TTHP-PhNCS-RGD}$: ESI-MS: m/z for $\text{C}_{72}\text{H}_{97}\text{N}_{19}\text{O}_{17}\text{S}_2 + 3\text{H}^+$ calc

522.23, found 522.24; HPLC: 220 nm, RT = 7.80 min, >98% purity (HPLC method 3).

Complexing $\text{H}_3\text{TTHP-NCS-RGD}$ and $\text{H}_3\text{TTHP-PhNCS-RGD}$ with $^{68}\text{Ga}^{3+}$ and $^{nat}\text{Ga}^{3+}$. Initial radiolabeling experiments utilized an Eckert & Ziegler $^{68}\text{Ge}/^{68}\text{Ga}$ generator. Aqueous HCl solution (0.1 M, 5 mL) was passed through the generator and the eluate was fractionated (5×1 mL). The second fraction (1 mL, containing 90–100 MBq ^{68}Ga) was added directly to an ethanol/water solution (50%/50%, 50–100 μL) of either $\text{H}_3\text{TTHP-NCS-RGD}$ (22.5 μg) or $\text{H}_3\text{TTHP-PhNCS-RGD}$ (25 μg), immediately followed by a solution of ammonium acetate (1 M, 300 μL). This solution was immediately applied to an analytical reverse-phase C18 HPLC column. [$^{68}\text{Ga}(\text{THP-NCS-RGD})$]: radiochemical yield >99% (HPLC), HPLC: RT = 7.83 min (HPLC method 3). [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$]: radiochemical yield >99% (HPLC), HPLC: RT = 8.15 min (HPLC method 3). For both conjugates, specific activity at calibration = 8–9 MBq nmol $^{-1}$ conjugate.

The nonradioactive analogues, [$^{nat}\text{Ga}(\text{THP-NCS-RGD})$] and [$^{nat}\text{Ga}(\text{THP-PhNCS-RGD})$], were also prepared. An aqueous solution of GaCl_3 (2 mg mL $^{-1}$, 5 μL , 50–60 nmol) was added to either $\text{H}_3\text{TTHP-NCS-RGD}$ (45 μg , ~24 nmol) or $\text{H}_3\text{TTHP-PhNCS-RGD}$ (50 μg , ~25 nmol) dissolved in deionized water (50 μL). The solutions were applied to an analytical reverse-phase C18 HPLC column and subjected to LCMS analysis. [$^{nat}\text{Ga}(\text{THP-NCS-RGD})$]: HPLC RT = 7.57 min (HPLC method 3); MS $\text{C}_{65}\text{H}_{88}\text{N}_{17}\text{O}_{17}\text{SGa} + 2\text{H}^+$, observed monoisotopic peak = 740.78, calculated = 740.78. [$^{nat}\text{Ga}(\text{THP-PhNCS-RGD})$]: HPLC RT = 8.15 min (HPLC method 3); MS $\text{C}_{72}\text{H}_{94}\text{N}_{19}\text{O}_{17}\text{S}_2\text{Ga} + 2\text{H}^+$, observed monoisotopic peak = 815.80, calculated 815.80.

For biodistribution studies, ^{68}Ga eluate from an iThemba Lab generator was preconditioned as previously described.⁴¹ Briefly, a cation exchange cartridge containing AG 50W \times 4 resin (50 mg) was conditioned by passing through aqueous HCl solution (4 M, 1 mL) and deionized water (1 mL) sequentially. To elute the $^{68}\text{Ge}/^{68}\text{Ga}$ generator, aqueous HCl solution (0.4 M, 5 mL) was passed through the generator and transferred directly onto the cation exchange cartridge. The cartridge was dried with air (1 mL), washed with 0.15 M HCl in water/ethanol (20%/80%), and again dried with air (1 mL). A solution of 0.9 M HCl in water/ethanol (200 μL , 10%/90%) was used to elute ^{68}Ga (800–1000 MBq), which was diluted to a volume of 1 mL with deionized water. Lyophilized peptide conjugate— $\text{H}_3\text{TTHP-NCS-RGD}$ (22.5 μg , trifluoroacetate salt) or $\text{H}_3\text{TTHP-PhNCS-RGD}$ (25 μg , trifluoroacetate salt)—dissolved in 20–40 μL of water/ethanol (50%/50%) was added to the solution containing ^{68}Ga , immediately followed by a solution of ammonium acetate (2 M, 400 μL) and 0.9% saline (1100 μL). An aliquot for ITLC analysis was immediately applied to an ITLC-SG plate. The ITLC-SG plate was developed using an aqueous citrate buffer (0.1 M, pH 5.5) mobile phase. [$^{68}\text{Ga}(\text{THP-NCS-RGD})$] and [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$]: R_f < 0.1; [$^{68}\text{Ga}(\text{citrate})_2$] $^{3-}$: R_f > 0.8. [$^{68}\text{Ga}(\text{THP-NCS-RGD})$]: radiochemical yield = 96–98% (ITLC), HPLC: RT = 9.42 min (HPLC method 4). [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$]: radiochemical yield = 97–99% (ITLC), HPLC: RT = 9.78 min (HPLC method 4). For both conjugates, specific activity at dose measurement = 60–80 MBq nmol $^{-1}$ conjugate.

Serum Stability Studies. Solutions containing [$^{68}\text{Ga}(\text{THP-NCS-RGD})$] and [$^{68}\text{Ga}(\text{THP-PhNCS-RGD})$] (each 250 μL , containing 50 MBq $^{68}\text{Ga}^{3+}$ and ~5 μg of peptide conjugate, synthesized using eluate from an Eckert and Ziegler

generator as described above) were added to 1.25 mL of fresh human female O⁺ serum, and incubated at 37 °C for 4 h. At 1 and 4 h, aliquots were applied to a size exclusion HPLC column. Solutions of [⁶⁸Ga(THP-NCS-RGD)] and [⁶⁸Ga(THP-PhNCS-RGD)] were also separately subjected to size exclusion chromatographic analysis to determine retention times. A solution of ⁶⁸Ga³⁺ in 0.33 M ammonium acetate (10 MBq, 50 μL) was added to 250 μL of serum and incubated at 37 °C for 1 h to determine the retention time of ⁶⁸Ga³⁺-bound serum proteins.

Metabolic Stability Studies. Solutions containing [⁶⁸Ga(THP-NCS-RGD)] and [⁶⁸Ga(THP-PhNCS-RGD)] (synthesized using eluate from an Eckert and Ziegler generator as described above) were diluted with physiological saline solution (15–30 MBq of each radiotracer containing 1–3 μg conjugate) and administered intravenously to seven- to nine-week-old female Balb/c mice (Harlan, UK) under isoflurane anesthesia. At 20 or 90 min PI, animals were euthanized, and serum and urine samples collected and analyzed using analytical reverse-phase HPLC (method 3).

Determination of IC₅₀. The relative affinity of [Ga(THP-NCS-RGD)], [Ga(THP-PhNCS-RGD)], and RGD for integrin α_vβ₃ was determined in a solid-phase competitive binding assay^{45,47} with ¹²⁵I-echistatin (PerkinElmer, Boston). In brief, wells of a 96 well plate were coated with integrin α_vβ₃ (150 ng mL⁻¹) in coating buffer (100 μL, 25 mM Tris HCl pH 7.4, 150 mM NaCl, 1 mM CaCl₂, 0.5 mM MgCl₂, and 1 mM MnCl₂) overnight at 4 °C. Wells were then washed twice in binding buffer (coating buffer containing 0.1% bovine serum albumin (w/v) (BSA)) before being blocked for 2 h at room temperature with blocking buffer (coating buffer containing 1% BSA (w/v)). After a further two washes in binding buffer, ¹²⁵I-echistatin (0.5 kBq) and [Ga(THP-NCS-RGD)], [Ga(THP-PhNCS-RGD)], or RGD were added simultaneously (to a total volume of 100 μL, and a conjugate/(RGDfK) concentration of 10 000 nM to 0.001 nM) for 1 h at room temperature, before being washed twice as before. Finally, the amount of activity bound to the wells via integrin α_vβ₃ was counted using a Wallac 1282 Compugamma Universal Gamma Counter. Measurements at each concentration for each compound were obtained in sextuplicate. IC₅₀ values were calculated using a nonlinear regression model (Binding/Saturation, one site–total) in GraphPad Prism 5.04.

PET Scanning and Biodistribution. All animal experiments were performed with approval from the Peter MacCallum animal ethics committee. Six- to eight-week-old Balb/c nude mice (Animal Resources Centre, Western Australia) were implanted subcutaneously on the right flank with 4 million U87MG cells. Once the tumors reached a volume of >250 mm³ the animals were injected intravenously with 13–20 MBq [⁶⁸Ga(THP-NCS-RGD)] (containing 1 μg of H₃THP-NCS-RGD). For blocking studies, animals were coinjected with RGD peptide (400 μg). At 1 and 2 h, the animals were anaesthetized and imaged on a Philips MOSAIC small animal PET scanner. The images were reconstructed using a 3D RAMLA algorithm and tracer uptake determined as described previously.⁴⁸ On completion of the scan animals were euthanized and tissues harvested, weighed, and radioactivity counted using a Gamma Counter (Biomedex).

■ ASSOCIATED CONTENT

§ Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.bioconjchem.5b00335.

HPLC chromatograms, serum stability, metabolic stability and biodistribution data (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: michelle.ma@kcl.ac.uk.

Author Contributions

All authors have given approval to the final version of the manuscript.

Notes

The authors declare the following competing financial interest(s): PJB holds patents whose claims encompass the newly described chelators. All other authors declare that they have no conflict of interest.

■ ACKNOWLEDGMENTS

M.T.M. acknowledges the support of the People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme (FP7/2007-2013) under REA grant agreement number 299009, and the Royal Society of Chemistry through a Researcher Mobility Fellowship. S.Y.A.T. was supported by a grant from Leukaemia and Lymphoma Research. J.B.-T. was supported by a grant from the Alzheimer's Society. We thank Wayne Noonan, Kerry Ardley, and Rachael Walker for expert technical support. We thank David C. Muller (Genetic Epidemiology Group, International Agency for Research on Cancer) for his statistical advice and support. This research was supported by the Centre of Excellence in Medical Engineering funded by the Wellcome Trust and EPSRC (WT088641/Z/09/Z), the KCL and UCL Comprehensive Cancer Imaging Centre funded by CRUK and EPSRC in association with the MRC and DoH (England), and by the NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the DoH.

■ REFERENCES

- (1) Price, E. W., and Orvig, C. (2014) Matching chelators to radiometals for radiopharmaceuticals. *Chem. Soc. Rev.* 43, 260–90.
- (2) Zeglis, B. M., Houghton, J. L., Evans, M. J., Viola-Villegas, N., and Lewis, J. S. (2014) Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals. *Inorg. Chem.* 53, 1880–99.
- (3) Velikyan, I. (2014) Prospective of ⁶⁸Ga-radiopharmaceutical development. *Theranostics* 4, 47–80.
- (4) Afshar-Oromieh, A., Zechmann, C. M., Malcher, A., Eder, M., Eisenhut, M., Linhart, H. G., Holland-Letz, T., Hadaschik, B. A., Giesel, F. L., Debus, J., et al. (2014) Comparison of PET imaging with a ⁶⁸Ga-labelled PSMA ligand and ¹⁸F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. *Eur. J. Nucl. Med. Mol. Imaging* 41, 11–20.
- (5) Hofman, M. S., Kong, G., Neels, O. C., Eu, P., Hong, E., and Hicks, R. J. (2012) High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. *J. Med. Imaging Radiat Oncol* 56, 40–7.
- (6) Ambrosini, V., Campana, D., Tomassetti, P., and Fanti, S. (2012) ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. *Eur. J. Nucl. Med. Mol. Imaging* 39, 52–60.

- (7) Srirajaskanthan, R.; Kayani, I.; Quigley, A. M.; Soh, J.; Caplin, M. E., and Bomanji, J. (2010) The role of ^{68}Ga -DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on ^{111}In -DTPA-octreotide scintigraphy. *J. Nucl. Med.* 51, 875–82.
- (8) Haug, A. R.; Auernhammer, C. J.; Wangler, B.; Schmidt, G. P.; Uebels, C.; Goke, B.; Cumming, P.; Bartenstein, P.; Tiling, R.; and Hacker, M. (2010) ^{68}Ga -DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. *J. Nucl. Med.* 51, 1349–56.
- (9) Conry, B. G.; Papathanasiou, N. D.; Prakash, V.; Kayani, I.; Caplin, M.; Mahmood, S.; and Bomanji, J. B. (2010) Comparison of ^{68}Ga -DOTATATE and ^{18}F -fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. *Eur. J. Nucl. Med. Mol. Imaging* 37, 49–57.
- (10) Ferreira, C. L.; Lamsa, E.; Woods, M.; Duan, Y.; Fernando, P.; Bensimon, C.; Kordos, M.; Guenther, K.; Jurek, P.; and Kiefer, G. E. (2010) Evaluation of bifunctional chelates for the development of gallium-based radiopharmaceuticals. *Bioconjugate Chem.* 21, 531–6.
- (11) Mueller, D.; Klette, I.; Baum, R. P.; Gottschaldt, M.; Schultz, M. K.; and Breeman, W. A. P. (2012) Simplified NaCl based ^{68}Ga concentration and labeling procedure for rapid synthesis of ^{68}Ga radiopharmaceuticals in high radiochemical purity. *Bioconjugate Chem.* 23, 1712–7.
- (12) Zhernosekov, K. P.; Filosofov, D. V.; Baum, R. P.; Aschoff, P.; Bihl, H.; Razbash, A. A.; Jahn, M.; Jennewein, M.; and Roesch, F. (2007) Processing of generator-produced ^{68}Ga for medical application. *J. Nucl. Med.* 48, 1741–8.
- (13) Velikyan, I.; Maecke, H.; and Langstrom, B. (2008) Convenient preparation of ^{68}Ga -based PET-radiopharmaceuticals at room temperature. *Bioconjugate Chem.* 19, 569–73.
- (14) Eisenwiener, K.-P.; Prata, M. I. M.; Buschmann, I.; Zhang, H.-W.; Santos, A. C.; Wenger, S.; Reubi, J. C.; and Maecke, H. R. (2002) NODAGATOC, a new chelator-coupled somatostatin analogue labeled with $^{67/68}\text{Ga}$ and ^{111}In for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. *Bioconjugate Chem.* 13, 530–41.
- (15) Fani, M.; Braun, F.; Waser, B.; Beetschen, K.; Cescato, R.; Erchegyi, J.; Rivier, J. E.; Weber, W. A.; Maecke, H. R.; and Reubi, J. C. (2012) Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. *J. Nucl. Med.* 53, 1481–9.
- (16) Morfin, J.-F., and Toth, E. (2011) Kinetics of $\text{Ga}(\text{NOTA})$ formation from weak Ga -citrate complexes. *Inorg. Chem.* 50, 10371–8.
- (17) Liu, Z.; Niu, G.; Wang, F.; and Chen, X. (2009) ^{68}Ga -labeled NOTA -RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. *Eur. J. Nucl. Med. Mol. Imaging* 36, 1483–94.
- (18) de Sa, A.; Matias, A. A.; Prata, M. I. M.; Geraldes, C. F. G. C.; Ferreira, P. M. T.; and Andre, J. P. (2010) Gallium labeled NOTA -based conjugates for peptide receptor-mediated medical imaging. *Bioorg. Med. Chem. Lett.* 20, 7345–8.
- (19) Oxboel, J.; Brandt-Larsen, M.; Schjoeth-Eskesen, C.; Myschetzky, R.; El-Ali, H. H.; Madsen, J.; and Kjaer, A. (2014) Comparison of two new angiogenesis PET tracers ^{68}Ga -NODAGA- $\text{E}[\text{c}(\text{RGDyK})]_2$ and ^{64}Cu -NODAGA- $\text{E}[\text{c}(\text{RGDyK})]_2$; in vivo imaging studies in human xenograft tumors. *Nucl. Med. Biol.* 41, 259–67.
- (20) Dumont, R. A.; Deininger, F.; Haubner, R.; Maecke, H. R.; Weber, W. A.; and Fani, M. (2011) Novel ^{64}Cu - and ^{68}Ga -labeled RGD conjugates show improved PET imaging of $\alpha_v\beta_3$ integrin expression and facile radiosynthesis. *J. Nucl. Med.* 52, 1276–84.
- (21) Simecek, J.; Schulz, M.; Notni, J.; Plutnar, J.; Kubicek, V.; Havlickova, J.; and Hermann, P. (2012) Complexation of metal ions with TRAP (1,4,7-triazacyclononane phosphinic acid) ligands and 1,4,7-triazacyclononane-1,4,7-triacetic acid: phosphinate-containing ligands as unique chelators for trivalent gallium. *Inorg. Chem.* 51, 577–90.
- (22) Simecek, J.; Hermann, P.; Wester, H.-J.; and Notni, J. (2013) How is ^{68}Ga labeling of macrocyclic chelators influenced by metal ion contaminants in $^{68}\text{Ge}/^{68}\text{Ga}$ generator eluates? *ChemMedChem* 8, 95–103.
- (23) Notni, J.; Pohle, K.; and Wester, H.-J. (2012) Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET. *EJNMMI Research* 2 (28), 5.
- (24) Notni, J.; Hermann, P.; Havlickova, J.; Kotek, J.; Kubicek, V.; Plutnar, J.; Loktionova, N.; Riss, P. J.; Rosch, F.; and Lukes, I. (2010) A triazacyclononane-based bifunctional phosphinate ligand for the preparation of multimeric ^{68}Ga tracers for positron emission tomography. *Chem. - Eur. J.* 16, 7174–85.
- (25) Notni, J.; Simecek, J.; Hermann, P.; and Wester, H.-J. (2011) TRAP, a Powerful and Versatile Framework for Gallium-68 Radiopharmaceuticals. *Chem. - Eur. J.* 17, 14718–22.
- (26) Notni, J.; Pohle, K.; and Wester, H.-J. (2013) Be spoilt for choice with radiolabelled RGD peptides: Preclinical evaluation of ^{68}Ga -TRAP(RGD) $_3$. *Nucl. Med. Biol.* 40, 33–41.
- (27) Simecek, J.; Notni, J.; Kapp, T. G.; Kessler, H.; and Wester, H.-J. (2014) Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of ^{68}Ga -NOPO-c(RGDfK). *Mol. Pharmaceutics* 11, 1687–95.
- (28) Ma, M. T.; Neels, O. C.; Denoyer, D.; Roselt, P.; Karas, J. A.; Scanlon, D. B.; White, J. M.; Hicks, R. J.; and Donnelly, P. S. (2011) Gallium-68 complex of a macrobicyclic cage amine chelator tethered to two integrin-targeting peptides for diagnostic tumor imaging. *Bioconjugate Chem.* 22, 2093–103.
- (29) Ferreira, C. L.; Yapp, D. T. T.; Mandel, D.; Gill, R. K.; Boros, E.; Wong, M. Q.; Jurek, P.; and Kiefer, G. E. (2012) ^{68}Ga small peptide imaging: comparison of NOTA and PCTA. *Bioconjugate Chem.* 23, 2239–46.
- (30) Eder, M.; Schaefer, M.; Bauder-Wuest, U.; Hull, W.-E.; Waengler, C.; Mier, W.; Haberkorn, U.; and Eisenhut, M. (2012) ^{68}Ga -complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. *Bioconjugate Chem.* 23, 688–97.
- (31) Waldron, B. P.; Parker, D.; Burchardt, C.; Yufit, D. S.; Zimny, M.; and Roesch, F. (2013) Structure and stability of hexadentate complexes of ligands based on AAZTA for efficient PET labelling with gallium-68. *Chem. Commun.* 49, 579–81.
- (32) Knetsch, P. A.; Zhai, C.; Rangger, C.; Blatzer, M.; Haas, H.; Kaepooukum, P.; Haubner, R.; and Decristoforo, C. (2015) [^{68}Ga]-FSC-(RGD) $_3$ a trimeric RGD peptide for imaging $\alpha_v\beta_3$ integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation. *Nucl. Med. Biol.* 42, 115–22.
- (33) Boros, E.; Ferreira, C. L.; Cawthray, J. F.; Price, E. W.; Patrick, B. O.; Wester, D. W.; Adam, M. J.; and Orvig, C. (2010) Acyclic chelate with ideal properties for ^{68}Ga PET imaging agent elaboration. *J. Am. Chem. Soc.* 132, 15726–33.
- (34) Boros, E.; Ferreira, C. L.; Yapp, D. T. T.; Gill, R. K.; Price, E. W.; Adam, M. J.; and Orvig, C. (2012) RGD conjugates of the H_2dedpa scaffold: synthesis, labeling and imaging with ^{68}Ga . *Nucl. Med. Biol.* 39, 785–94.
- (35) Ramogida, C. F.; Cawthray, J. F.; Boros, E.; Ferreira, C. L.; Patrick, B. O.; Adam, M. J.; and Orvig, C. (2015) $\text{H}_2\text{CHXdedpa}$ and $\text{H}_4\text{CHXoctapa}$ -chiral acyclic chelating ligands for $^{67/68}\text{Ga}$ and ^{111}In radiopharmaceuticals. *Inorg. Chem.* 54, 2017–31.
- (36) Berry, D. J.; Ma, Y.; Ballinger, J. R.; Tavare, R.; Koers, A.; Sunassee, K.; Zhou, T.; Nawaz, S.; Mullen, G. E. D.; Hider, R. C.; et al. (2011) Efficient bifunctional gallium-68 chelators for positron emission tomography: tris(hydroxypyridinone) ligands. *Chem. Commun.* 47, 7068–70.
- (37) Ma, M. T.; Meszaros, L. K.; Paterson, B. M.; Berry, D. J.; Cooper, M. S.; Ma, Y.; Hider, R. C.; and Blower, P. J. (2015) Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with $^{89}\text{Zr}^{4+}$: comparison with desferrioxamine-B. *Dalton Trans.* 44, 4884–900.
- (38) Zhou, T.; Neubert, H.; Liu, D. Y.; Liu, Z. D.; Ma, Y. M.; Kong, X. L.; Luo, W.; Mark, S.; and Hider, R. C. (2006) Iron binding dendrimers: a novel approach for the treatment of hemochromatosis. *J. Med. Chem.* 49, 4171–82.

- (39) Munch, H., Hansen, J. S., Pittelkow, M., Christensen, J. B., and Boas, U. (2008) A new efficient synthesis of isothiocyanates from amines using di-*tert*-butyl dicarbonate. *Tetrahedron Lett.* 49, 3117–9.
- (40) Kerr, J. S., Slee, A. M., and Mousa, S. A. (2000) Small molecule α_v integrin antagonists: novel anticancer agents. *Expert Opin. Invest. Drugs* 9, 1271–9.
- (41) Eppard, E., Wuttke, M., Nicodemus, P. L., and Roesch, F. (2014) Ethanol-based post-processing of generator-derived ^{68}Ga toward kit-type preparation of ^{68}Ga -radiopharmaceuticals. *J. Nucl. Med.* 55, 1023–8.
- (42) Yu, H. M., Chen, S. T., and Wang, K. T. (1992) Enhanced coupling efficiency in solid-phase peptide synthesis by microwave irradiation. *J. Org. Chem.* 57, 4781–4.
- (43) Terry, S. Y. A., Abiraj, K., Frielink, C., van Dijk, L. K., Bussink, J., Oyen, W. J., and Boerman, O. C. (2014) Imaging integrin $\alpha_v\beta_3$ on blood vessels with ^{111}In -RGD₂ in head and neck tumor xenografts. *J. Nucl. Med.* 55, 281–6.
- (44) Hernandez, R., Valdovinos, H. F., Yang, Y., Chakravarty, R., Hong, H., Barnhart, T. E., and Cai, W. (2014) ^{44}Sc : An attractive isotope for peptide-based PET imaging. *Mol. Pharmaceutics* 11, 2954–61.
- (45) Maschauer, S., Haubner, R., Kuwert, T., and Prante, O. (2014) ^{18}F -Glyco-RGD peptides for PET imaging of integrin expression: efficient radiosynthesis by click chemistry and modulation of biodistribution by glycosylation. *Mol. Pharmaceutics* 11, 505–15.
- (46) Liu, S., Liu, Z., Chen, K., Yan, Y., Watzlowik, P., Wester, H.-J., Chin, F. T., and Chen, X. (2010) ^{18}F -labeled galacto and PEGylated RGD dimers for PET imaging of $\alpha_v\beta_3$ integrin expression. *Mol. Imaging Biol.* 12, 530–8.
- (47) Dijkgraaf, I., Terry, S. Y. A., McBride, W. J., Goldenberg, D. M., Laverman, P., Franssen, G. M., Oyen, W. J. G., and Boerman, O. C. (2013) Imaging integrin $\alpha_v\beta_3$ expression in tumors with an ^{18}F -labeled dimeric RGD peptide. *Contrast Media Mol. Imaging* 8, 238–45.
- (48) Paterson, B. M., Roselt, P., Denoyer, D., Cullinane, C., Binns, D., Noonan, W., Jeffery, C. M., Price, R. I., White, J. M., Hicks, R. J., et al. (2014) PET imaging of tumours with a ^{64}Cu labeled macrobicyclic cage amine ligand tethered to Tyr³-octreotate. *Dalton Trans.* 43, 1386–96.